Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Time to Buy?

Key Points

• Stock gapped up premarket — the shares opened at $41.90 after a $39.79 close and last traded at $41.50 on very light volume (600 shares).
• The stock holds a consensus rating of “Moderate Buy” (three Strong Buy, five Hold), with recent analyst moves including BTIG raising to Strong-Buy and BNP Paribas downgrading from Strong-Buy to Hold.
• Zealand reported quarterly EPS of −$0.81, beating estimates of −$1.34 but missing revenue expectations ($10.79M vs. $19.69M); the company has a $2.86B market cap and analysts forecast −2.19 EPS for the year.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $39.79, but opened at $41.90. Zealand Pharma A/S shares last traded at $41.50, with a volume of 600 shares traded.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. BTIG Research raised shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Friday, November 28th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Cantor Fitzgerald reissued a "neutral" rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane cut Zealand Pharma A/S from a "strong-buy" rating to a "hold" rating in a research report on Friday, March 6th. Finally, William Blair restated a "market perform" rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Three research analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy".

Zealand Pharma A/S Trading Up 1.0%

The stock has a 50-day moving average price of $62.13 and a two-hundred day moving average price of $70.24. The stock has a market capitalization of $2.86 billion, a PE ratio of 2.94 and a beta of 0.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 49.76%. The firm had revenue of $10.79 million during the quarter, compared to analysts' expectations of $19.69 million. As a group, equities analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand's pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.